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A CASE OF HASHIMOTO’S ENCEPHALOPATHY IN A PATIENT WITH SUSPECTED LITHIUM TOXICITY
ABSTRACT
Hashimoto’s encephalopathy is a rare neurological disorder of unknown etiology. We presented, a case of  middle aged 
male with bipolar disorder on Lithium carbonate for 30 years, admitted with altered behavior for 2 weeks and high 
Lithium levels. He was admitted with the suspicion of Lithium toxicity. EEG showed generalized epileptiform discharges. 
MRI brain revealed frontal cortical atrophy. CSF detailed report was normal. Further workup showed a high TSH level 
and positive anti-TPO (anti thyroid peroxidase) antibodies. Based on clinical picture, raised antibodies and no 
discernible cause, diagnosis of probable Hashimoto’s encephalopathy was made. He received pulse of 
methylprednisolone for five days and his symptoms improved dramatically. Our case report highlights the importance 
of diagnosing a rare neurological syndrome in a complex clinical scenario.
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C A S E  R E P O R T
INTRODUCTION:
Hashimoto’s encephalopathy (HE) is an uncommon 
neurological syndrome associated with Hashimoto’s 
thyroiditis, first reported by Brain et al in 1966.(1) The 
disease includes a wide spectrum of neurologic 
symptoms ranging from stroke like presentation to 
diffuse progressive pattern of slow cognitive decline 
with dementia, confusion and hallucination.Treatment 
with corticosteroids is almost always successful. Other 
forms of immunomodulation, such as intravenous 
immune-globulin and plasma exchange, may also be 
effective.
CASE REPORT:
A 55 years old businessman, known case of 
Hypertension and Bipolar disorder for 30 years was 
admitted through outpatient department with irrelevant 
talking for 2 weeks. His family was concerned for the 
recent changes in the patient’s behaviour as he was 
not recognizing, passing stool in the bedroom, 
extremely irritable and agitated. He also left home for 2 
days and was found unresponsive outside shopping 
mall. During these two weeks patient has been 
unpredictable, shouting obscenities, responding to 
internal stimuli and smiling. He developed tremors in 
both hands 6 months back and there was a history of 
stimulant use in the past.  He was being treated for 
bipolar disorder with Lithium 300mg thrice daily and 
Carbamazepine 200 mg twice daily for the past 30 
years and was on  Lisinopril 5 mg daily for hypertension. 
Before illness he usually have mood swings but able to 
perform his work well. On examination, he was a 
middle-aged male, lying on bed, conscious, aggressive, 
not following commands and with significant palilalia. 
Neurological examination showed grossly intact cranial 
nerves, increased tone in all four limbs, no focal deficit, 
normal reflexes and downgoing plantars .No signs of 
meningeal irritation, nystagmus or myoclonus. Baseline 
workup revealed Hemoglobin of 9.6 gm/dl (Normocytic 
normochromic) deranged renal parameters (urea:150 
mg/dl,Creatinine:3.44 mg/dl) , TSH of 6 Miu/L(0.4-4) 
Lithium levels of 3.9 mmol/L (0.4-2 mmol/L ) His 
lithium was stopped and intravenous hydration was 
started. EEG showed generalized epileptiform 
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discharges. MRI brain showed frontal cortical atrophy, 
without any contrast enhancement. CSF detailed report 
was unremarkable. HIV and VDRL serologies were 
negative. Patient was started on Acyclovir and Sodium 
valproate due to the presence of epileptiform 
discharges. Carbamazepine was continued. He 
received Haloperidol and later, kept on Queitiapine (25 
mg twice a day) for agitation. During the seven days of 
hospital stay despite of correction of metabolic 
parameters patient did not show any improvement. 
HSV PCR came out as negative. His workup  (anti 
NMDA antibodies, anti GABA antibodies) for 
autoimmune encephalitis was negative. Anti TPO 
(anti-thyroid peroxidase) came out to be positive and 
patient was given pulse of methylprednisolone for 5 
days. His symptoms improved dramatically and he was 
discharged after 7 days, on tapering doses of steroids.
DISCUSSION: 
Hashimoto’s encephalopathy (HE) is an uncommon 
neurologic syndrome associated with Hashimoto’s 
thyroiditis, first reported by Brain et al in 1966. He 
reported an individual with autoimmune thyroid disease 
who presented with recurrent stroke-like episodes 
occurring independently of the thyroid status.1,2
The etiology of HE remains unclear. The mechanism of 
HE does not appear to be related to the thyroid status 
and varies from patient to patient. In two recent 
reviews, 23% to 35% of patients had subclinical 
hypothyroidism, 17% to 20% had hypothyroidism, 7% 
had hyperthyroidism and 18% to 45% were euthyroid.4 
Our reported case was hypothyroid. The development of 
neurological symptoms may occur 
A hospital based epidemiologic study on 
symptomatology consistent with HE showed prevalence 
to be about 2.1 per 100,000.3 The disorder occurs 
more frequently between age 44 to 46 years, with a 
female-to-male ratio of four to one, consistent with our 
patient.
Literature reviews suggests two major patterns of 
presentation about 25% of patients followed a 
stroke-like pattern of multiple recurrent episodes of 
focal neurologic deficits with a variable degree of 
cognitive dysfunction and consciousness impairment, 
remaining 75% present with a diffuse progressive 
pattern of slow cognitive decline with dementia, 
confusion and hallucinations.3
Shaw et al proposed the diagnostic criteria for HE 
based on the presence of cognitive impairment with or 
without neuropsychiatric symptoms; seizures; 
stroke-like events; focal neurological deficit or 
movement disorders; elevated antithyroid antibodies; 
and corticosteroid responsiveness.4
EEG abnormalities are seen in 90% to 98% of patients 
with HE, usually a nonspecific slow background activity. 
Focal spikes or sharp waves and transient epileptic 
activity are less common5 
EEG performed on two occasions in our patient showed 
generalized epileptiform discharges.
In a review of 82 patients with HE, brain computed 
tomography or MRI showed abnormalities in 49% such 
as cerebral atrophy, focal cortical abnormality, diffuse 
subcortical abnormality and nonspecific subcortical 
focal white matter abnormality6. Our patient showed 
frontal cortical atrophy with no parenchymal 
abnormalities, which is either due to bipolar disorder or 
a part of  Hashimoto’s encephalopathy.
Elevated titers of antithyroid antibodies (especially 
TPO-Ab) are the most relevant paraclinical finding, 
which could be considered to be a hallmark of 
HE.Presented case showed, that all patients with 
progressive cognitive impairment or with a dementia of 
unclear origin should be tested for HE.
The diagnosis of HE should be considered even if 
Hashimoto's thyroiditis is not known in patients with 
euthyroid states but with high serum and/or CSF titers 
of antithyroid antibodies.  About 50% of cases are 
non-responders to corticosteroid therapy, thus 
non-responsiveness should not be exclusion criteria for 
HE, other therapeutic strategies should be tried: 
immunosuppressive therapy (azathioprine or 
cyclophosphamide) and recently proposed in some 
cases plasmapharesis or intravenous immunoglobulins. 
Our patient responded well to corticosteroid pulse 
therapy.7,8
Our patient was admitted with the suspicion of Lithium 
toxicity due to high serum lithium levels. Laboratory 
workup revealed high urea. His mental status did not 
improve despite the correction of deranged metabolic 
parameters. We exclude all other infective causes of 
encephalopathy by MRI brain and CSF studies. This led 
us to think of atypical causes of encephalopathy like 
NMDA encephalitis and Hashimoto’s encephalopathy. 
Positive anti thyroid peroxidase antibodies and dramatic 
response to steroids prove it to be a case of 
Hashimoto’s encephalopathy.
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FIGURE LEGEND:
T2 Weighted image showed significant frontal cortical 
atrophy .
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